InfraReDx, Inc., a Burlington, Massachusetts-based medical device company providing intelligent cardiovascular diagnostic imaging technologies, has raised $24.1m from existing shareholders.
The company intends to use the funds to expand manufacturing operations and infrastructure to support the commercialization of the LipiScan™ IVUS Coronary Imaging System. The proceeds will also enable InfraReDx to conduct new clinical trials investigating expanded clinical applications of the system.
LipiScan IVUS, which includes a cardiac catheter to combine intravascular ultrasound (IVUS) and near-infrared (NIR) spectroscopy, is designed to help cardiologists identify and characterize the plaques known to complicate stenting and suspected to cause most heart attacks.
Founded in 1998 and led by President and CEO Donald Southard, InfraReDx launched the system in September 2010 after receiving U.S. Food and Drug Administration (FDA) approval.